Exchange: NASDAQ·Updated 07:30 PM EDT

MEDP News

News
all
press releases
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
Zacks
More News
President & CEO Of Medpace Holdings Makes $403K Sale
August J Troendle, President & CEO at Medpace Holdings (NASDAQ:MEDP), disclosed an insider sell on August 31, according to a recent SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchangeread more...
Benzinga
Why Medpace (MEDP) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
Teladoc (TDOC) Down 3.3% Since Last Earnings Report: Can It Rebound?
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
President & CEO At Medpace Holdings Sells $2.90M Of Stock
August J Troendle, President & CEO at Medpace Holdings (NASDAQ:MEDP), disclosed an insider sell on August 27, according to a recent SEC filing. What Happened: Troendle's decision to sell 4,673 shares of Medpaceread more...
Benzinga
CON vs. MEDP: Which Stock Should Value Investors Buy Now?
CON vs. MEDP: Which Stock Is the Better Value Option?
Zacks
Can AI Innovation and CRM Wins Boost Veeva Systems' Q2 Results?
VEEV heads into Q2 with Falcon AI, Vault CRM wins and R&D Cloud growth in focus as revenue and EPS estimates point to double-digit gains.
Zacks
Why Is Medpace (MEDP) Up 1.1% Since Last Earnings Report?
Medpace (MEDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?
Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.
Zacks
Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Zacks

Advertisement|Remove ads.